Cargando…

Beta-Endorphin and Oxytocin in Patients with Alcohol Use Disorder and Comorbid Depression

Background: The neuropeptides β-endorphin and oxytocin are released into the bloodstream as hormones from the pituitary gland but also have an important function as neuroregulators in the forebrain. The blood levels of both polypeptides have been shown to reflect depressive symptoms. β-Endorphin, in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roschina, Olga V., Levchuk, Lyudmila A., Boiko, Anastasiia S., Michalitskaya, Ekaterina V., Epimakhova, Elena V., Losenkov, Innokentiy S., Simutkin, German G., Loonen, Anton J. M., Bokhan, Nikolay A., Ivanova, Svetlana A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658665/ https://www.ncbi.nlm.nih.gov/pubmed/34884397 http://dx.doi.org/10.3390/jcm10235696

Ejemplares similares

Exploring Brain Derived Neurotrophic Factor and Cell Adhesion Molecules as Biomarkers for the Transdiagnostic Symptom Anhedonia in Alcohol Use Disorder and Comorbid Depression
por: Levchuk, Lyudmila A., et al.
Publicado: (2020)

Serum Levels of S100B Protein and Myelin Basic Protein as a Potential Biomarkers of Recurrent Depressive Disorders
por: Levchuk, Lyudmila A., et al.
Publicado: (2023)

Association Between BDNF Gene Variant Rs6265 and the Severity of Depression in Antidepressant Treatment-Free Depressed Patients
por: Losenkov, Innokentiy S., et al.
Publicado: (2020)

The functional variant rs334558 of GSK3B is associated with remission in patients with depressive disorders
por: Levchenko, Anastasia, et al.
Publicado: (2018)

Limited Associations Between 5-HT Receptor Gene Polymorphisms and Treatment Response in Antidepressant Treatment-Free Patients With Depression
por: Ochi, Taichi, et al.
Publicado: (2019)

Preliminary Pharmacogenetic Study to Explore Putative Dopaminergic Mechanisms of Antidepressant Action
por: Ochi, Taichi, et al.
Publicado: (2021)

Influence of eight ABCB1 polymorphisms on antidepressant response in a prospective cohort of treatment‐free Russian patients with moderate or severe depression: An explorative psychopharmacological study with naturalistic design
por: Geers, Lisanne M., et al.
Publicado: (2021)

Association of Single Nucleotide Polymorphisms of Cytokine Genes with Depression, Schizophrenia and Bipolar Disorder
por: Mikhalitskaya, Ekaterina V., et al.
Publicado: (2023)

Serum BDNF’s Role as a Biomarker for Motor Training in the Context of AR-Based Rehabilitation after Ischemic Stroke
por: Koroleva, Ekaterina S., et al.
Publicado: (2020)

Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia
por: Boiko, Anastasiia S., et al.
Publicado: (2019)

Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia
por: Boiko, Anastasiia S, et al.
Publicado: (2020)

Adipocytokines and Metabolic Syndrome in Patients with Schizophrenia
por: Mednova, Irina A., et al.
Publicado: (2020)

Cytokines as Potential Biomarkers of Clinical Characteristics of Schizophrenia
por: Mednova, Irina A., et al.
Publicado: (2022)

Cell Adhesion Molecules in Schizophrenia Patients with Metabolic Syndrome
por: Boiko, Anastasiia S., et al.
Publicado: (2023)

Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome
por: Boiko, Anastasiia S., et al.
Publicado: (2022)

Serum Growth Factors in Schizophrenia Patients
por: Boiko, Anastasiia S., et al.
Publicado: (2023)

Association of ANKK1 polymorphism with antipsychotic‐induced hyperprolactinemia
por: Fedorenko, Olga Yu., et al.
Publicado: (2020)

NRG1, PIP4K2A, and HTR2C as Potential Candidate Biomarker Genes for Several Clinical Subphenotypes of Depression and Bipolar Disorder
por: Levchenko, Anastasia, et al.
Publicado: (2020)

Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics
por: Boiko, Anastasiia S., et al.
Publicado: (2021)

A New Paradigm to Indicate Antidepressant Treatments
por: Loonen, Anton J. M., et al.
Publicado: (2021)

Neuron-specific enolase during the therapy in patients with alcohol use disorder and mood disorders
por: Levchuk, L., et al.
Publicado: (2021)

Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia
por: Pozhidaev, Ivan V, et al.
Publicado: (2020)

Protective Effects of Pyruvic Acid Salt Against Lithium Toxicity and Oxidative Damage in Human Blood Mononuclear Cells
por: Plotnikov, Evgenii, et al.
Publicado: (2019)

Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia
por: Paderina, Diana Z., et al.
Publicado: (2021)

Search for Possible Associations of FTO Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients
por: Boiko, Anastasiia S, et al.
Publicado: (2021)

Exploring the paradigm of depressive disorders through an evolutionary and biopsychosocial lens
por: Ochi, T., et al.
Publicado: (2023)

Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome
por: Kornetova, Elena G., et al.
Publicado: (2019)

Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients With Schizophrenia in Three Western Siberia Psychiatric Hospitals
por: Kornetova, Elena G., et al.
Publicado: (2021)

Gene Polymorphisms of Hormonal Regulators of Metabolism in Patients with Schizophrenia with Metabolic Syndrome
por: Boiko, Anastasiia S., et al.
Publicado: (2022)

Association of PIP4K2A Polymorphisms with Alcohol Use Disorder
por: Fedorenko, Olga Yu., et al.
Publicado: (2021)

The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia
por: Paderina, Diana Z., et al.
Publicado: (2022)

Building Predictive Models for Schizophrenia Diagnosis with Peripheral Inflammatory Biomarkers
por: Kozyrev, Evgeny A., et al.
Publicado: (2023)

PM515. The association between serotonin receptor gene polymorphisms and hyperprolactinemia in antipsychotic drug-treated schizophrenic patients
por: Ivanova, Svetlana, et al.
Publicado: (2016)

A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia
por: Osmanova, Diana Z., et al.
Publicado: (2019)

The difference in serum proteomes in schizophrenia and bipolar disorder
por: Smirnova, Liudmila, et al.
Publicado: (2019)

Association between 8 P‐glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug‐induced hyperprolactinaemia
por: Geers, Lisanne M., et al.
Publicado: (2020)

Genes of the Glutamatergic System and Tardive Dyskinesia in Patients with Schizophrenia
por: Fedorenko, Olga Yu., et al.
Publicado: (2022)

Association Study Indicates a Protective Role of Phosphatidylinositol-4-Phosphate-5-Kinase against Tardive Dyskinesia
por: Fedorenko, Olga Yu, et al.
Publicado: (2015)

5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia
por: Pozhidaev, Ivan V., et al.
Publicado: (2020)

Different Directions of Effects of Polyclonal IgG Antibodies from Patients with Schizophrenia and Healthy Individuals on Cell Death In Vitro: A Pilot Study
por: Epimakhova, Elena V., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7n183lvh6uhcmbqp4878i5q2l0